Podcast: Practice-Changing Advances in the Management of Hemophilia

STATEMENT OF NEED
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly, causing affected individuals to experience spontaneous bleeding as well as bleeding after injuries or surgery. The 2 most common types are hemophilia A, caused by low levels of clotting factor VIII; and hemophilia B, caused by low levels of clotting factor IX. The standard treatment for hemophilia involves replacing the missing blood clotting factor by infusing commercially prepared factor concentrates. However, approximately 15% to 20% of patients will develop an inhibitor, an antibody that prevents the clotting factor from working, resulting in increased complications and the need for more complex management (CDC, 2023). It is vital that clinicians remain up-to-date on the latest data on novel and emerging therapies for hemophilia A and B in order to provide the most tailored treatment options to their patients. In this Video Viewpoint Strategy Session, Dr. Guy Young, Director of the Hemostasis and Thrombosis Program and Professor of Pediatrics at Keck School of Medicine of the University of Southern California (USC), and Dr. Jennifer Davila, Co-Director of the Hemophilia Treatment Center at Montefiore and Associate Professor of Pediatrics at The Children’s Hospital at Montefiore, will explore practice-changing advances in the management of hemophilia.

TARGET AUDIENCE
Hematologists, internal medicine physicians, pediatricians, family medicine physicians, nurse practitioners, physician assistants, nurses, and other health care professionals (HCPs) involved in the treatment of patients with hemophilia.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to

Appraise the mechanisms of action, efficacy, safety, and indications of novel and emerging therapies for hemophilia A and B
Evaluate strategies to tailor treatment to individual patients with hemophilia
Assess approaches to address the problem of nonadherence to hemophilia treatment